Praxis Precision Medicines Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders such as epilepsy, movement disorders, and depression. Its approach uses genetic insights and neuroscience to target underlying brain-circuit dysfunctions. Praxis’s share performance is typically driven by trial readouts, regulatory progress, and investor sentiment toward innovative CNS drug development.